Bifogade filer
Kurs & Likviditet
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Gothenburg, Sweden, August 15, 2022 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-June 2022. Please register to attend the presentation in person latest on August 22. The interim report and presentation will be published on Wednesday, August 24 at 07:00 CET.
The presentation will be held on August 24, 2022, at 10:00 CET at the Infront Direkt Studio, Kungsgatan 33, in Stockholm. CEO Richard Godfrey, EVP and Head of R&D Nicholas Waters and CFO Viktor Siewertz will comment the interim report for the period January-June 2022. The presentation will be held in English and followed by a Q&A session.
To attend in-person, please register via email to ir@irlab.se.
It is also possible to follow the presentation online on: https://youtu.be/NHxs1EViwIM
The interim report and the slide deck will be available on www.irlab.se, and the recorded version of the presentation will be available shortly afterward.